Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Health systems and care delivery

Topic: Risk, prevention and care in population studies

Plain-language summary

Those who reached the DBT in both years had higher morbidity and utilization. In multivariate analyses, they were more likely than the 2006 only group to have one or more of 5 conditions (chronic pulmonary disease, dementia, depression, incontinence, and Parkinson disease), and within these conditions were more likely to use categories of trade-name medications for which there are limited available generic alternatives. Repeatedly reaching the DBT is a function of the extent and chronicity of disease burden and is characterized by conditions for which there is limited availability of generic medications, and associated common comorbidities. If these findings are confirmed, strategies at practice and policy levels may help such Medicare beneficiaries avoid unnecessary out of pocket expenditures on medications from prematurely reaching the DBT.

What this study adds

Evidence grade: Moderate

This study found that Medicare beneficiaries who repeatedly reached the drug benefit threshold were more likely to have conditions including dementia and to use trade-name medications with limited generic alternatives. It addresses medication costs in dementia but does not test any treatment, cure, or prevention for Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bayliss, E. A., Ellis, J., Delate, T., Steiner, J. F., & Raebel, M. A. (2010). Characteristics of Medicare Part D Beneficiaries Who Reach the Drug Benefit Threshold in Both of the First Two Years of the Part D Benefit. Medical Care. https://doi.org/10.1097/mlr.0b013e3181ca2824

Vancouver

Bayliss EA, Ellis J, Delate T, Steiner JF, Raebel MA. Characteristics of Medicare Part D Beneficiaries Who Reach the Drug Benefit Threshold in Both of the First Two Years of the Part D Benefit. Medical Care. 2010. doi:10.1097/mlr.0b013e3181ca2824. PMID: 20125044.

BibTeX

@article{bayliss2010-20125044,
  author  = {Bayliss, Elizabeth A. and Ellis, Jennifer and Delate, Thomas and Steiner, John F. and Raebel, Marsha A.},
  title   = {{Characteristics of Medicare Part D Beneficiaries Who Reach the Drug Benefit Threshold in Both of the First Two Years of the Part D Benefit}},
  journal = {Medical Care},
  year    = {2010},
  doi     = {10.1097/mlr.0b013e3181ca2824},
  pmid    = {20125044},
  url     = {https://doi.org/10.1097/mlr.0b013e3181ca2824}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study found that Medicare beneficiaries who repeatedly reached the drug benefit threshold were more likely to have conditions including dementia and to use trade-name medications with limited generic alternatives. It addresses medication costs in dementia but does not test any treatment, cure, or prevention for Alzheimer's disease.

Study details

How this study scored 43/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 0 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 43 of 100.43 of 100 points earned57 not earned

Published in a peer-reviewed journal, and it is a retrospective cohort study, reconstructed from past records. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Medical Care)
Journal's citation record 3 / 4 Medical Care: journal h-index 273 (OpenAlex, 2026-10-29)
Study design 7 / 12 A retrospective cohort study, reconstructed from past records
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2010 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 13 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.7 citations a year over 18 year(s) since 2010
Impact for its field and year 3 / 6 Cited 6.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Marsha A. Raebel: h-index 56 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Colorado Denver: institution h-index 907 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 20125044)
Free to read 0 / 2 Behind a paywall — scores zero
Total 43 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Health systems and care delivery from nearby years

Also tagged “palliative”

858 studies in the library carry the topic tag “palliative”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 858 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →